Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Make cold chain & temperature controlled logistics your domain
Find your reasons to attend 6th Cold Chain & Product Handling: Temperature Controlled Logistics forum
Amsterdam, January 12, 2016 – On the 17th of May, professionals from cold & supply chain, logistics, distribution, warehousing, quality assurance and validation, sales and operations planning, transport, packaging and shipping companies will gather in Amsterdam, the Netherlands, for the 6th Cold Chain & Product Handling: Temperature Controlled Logistics forum.
For three days, they will learn all about regulations, quality assurance and operational excellence as well as network through roundtable discussions, fishbowls, case studies and practical demonstrations of intelligent monitoring solutions.Professionals from companies such as Sanofi Pasteur, Eli Lilly, Merck Serono, Ferring Pharmaceuticals and more will provide updates on the current situation in the industry, predictions for 2020, GDP guidelines, data integrity and other interesting topics. Plus, before the forum starts, participants will have a chance to join a site visit to Schiphol Airport.
What are the presentations to look forward to?
For example, on the first day, the participants will have an opportunity to dive into the issue of the new GDP complement, provided by Mr. Sebastien Mauel, Head of Serialization and Product Security at Ferring Pharmaceuticals. Risk management and risk assessment will be addressed through a case study and presentation by Mr. Camillo Rossi of Eli Lilly.
The second day will be all about product handling & operational excellence and warehousing operational excellence. Themes such as ocean freight damage prevention, vaccine cold chain and more will be considered.
If you want to gain know-how, learn from the experience of top-level experts, find fresh ideas and create networking contacts that will enable you to make a difference in your company, this event is not to be missed.
In times of change, stay on top with the newest technology, thorough compliance, the most efficient packaging and the best risk management.For more information about the conference visit:
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.